- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IPI LEGACY LIQUIDATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| OCUGEN | 1,150 | +1,05 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| MAINZ BIOMED | 0,945 | -4,51 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,860 | +1,42 % | Cardiol Therapeutics legt Emissionsgarantievertrag und Optionsscheinvereinbarung vor | ||
| IBIO | 1,740 | -14,71 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,070 | +7,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| ATAIBECKLEY | 3,770 | +10,56 % | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | ||
| ALDEYRA | 4,700 | +0,38 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,700 | -0,80 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARDELYX | 6,170 | -0,58 % | Ardelyx, Inc.: Ardelyx Receives New Patent for Tenapanor | WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class... ► Artikel lesen | |
| CAPRICOR | 19,000 | -9,31 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| AKEBIA | 1,138 | -2,90 % | Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views |
Das Unternehmen IPI LEGACY LIQUIDATION CO kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IPI LEGACY LIQUIDATION CO finden Sie auf Wallstreet Online.